No Data
No Data
Libang Instruments (300206.SZ) announced first-quarter results, net profit of 38.52 million yuan, a year-on-year decrease of 72.56%
Libang Instruments (300206.SZ) disclosed its report for the first quarter of 2024. The company achieved 4.4 revenue during the reporting period...
Libang Instruments (300206.SZ) plans to pay 2.07 yuan for 10 shares to be deducted from interest on May 6
Libang Instruments (300206.SZ) announced that the company plans to distribute cash shares for every 10 shares in the 2023 annual equity distribution...
Libang Instruments (300206.SZ): As of April 10, 2024, the number of shareholders of the company was 28,555
Gelonghui, April 18 | Libang Instruments (300206.SZ) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 28,555.
“New” in terms of new quality productivity, Libang Digital Intelligence Chemical's new product CMEF was shocked by the release
SHENZHEN, April 14, 2024 /PRNewswire/ -- As the spring breeze blows past the Huangpu River, we know that the annual medical device event has begun again. In this vibrant time, the focus of the global medical community is once again on Shanghai, the Pearl of the Orient. Here, with 29 years of innovation and accumulation, Libang actively integrates into the overall development of the digital intelligence industry based on new quality productivity. With the theme of “wisdom • life”, Libang brought a new product launch ceremony to medical device colleagues and industry visitors. This is not only a demonstration of product innovation, but also a profound dialogue between technology and life. For exhibitors
Libang released its 2023 report: In vitro diagnosis revenue surged 19.79% year on year, and diversified businesses went hand in hand
SHENZHEN, March 30, 2024/PRNewswire/ -- On March 29, A-share listed company Libang Instruments (300206.SZ) disclosed its 2023 annual report. The report shows that in 2023, Libang achieved total revenue of 1,938 billion yuan, an increase of 11.22% over the previous year. The diversified business layout was continuously optimized to achieve steady operation and qualitative growth. Benefiting from product innovation, global localization, and improved organizational efficiency, Libang achieved year-on-year growth in domestic and international market revenue. In the domestic market, with the gradual growth of medical demand and the acceleration of domestic substitution, Libang relies on its technology and brand
Libang Instruments (300206.SZ): Net profit for 2023 will drop 5.00% to 221 million yuan, plan 10 to 2.07 yuan
On March 28, Ge Longhui (300206.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,938 billion yuan, an increase of 11.22%; net profit attributable to shareholders of listed companies was 221 million yuan, down 5.00% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 194 million yuan, down 3.19% year on year; basic income per share was 0.3818 yuan; it plans to distribute a cash dividend of 2.07 yuan (tax included) to all shareholders for every 10 shares.
No Data